[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2021000609A - Métodos de tratamiento con fármacos sustrato para cyp3a4. - Google Patents

Métodos de tratamiento con fármacos sustrato para cyp3a4.

Info

Publication number
MX2021000609A
MX2021000609A MX2021000609A MX2021000609A MX2021000609A MX 2021000609 A MX2021000609 A MX 2021000609A MX 2021000609 A MX2021000609 A MX 2021000609A MX 2021000609 A MX2021000609 A MX 2021000609A MX 2021000609 A MX2021000609 A MX 2021000609A
Authority
MX
Mexico
Prior art keywords
cyp3a4
treatment
patient
cyp3a4 substrate
substrate drug
Prior art date
Application number
MX2021000609A
Other languages
English (en)
Inventor
Christina Chow
Sundar Srinivasan
Original Assignee
Bow River LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bow River LLC filed Critical Bow River LLC
Publication of MX2021000609A publication Critical patent/MX2021000609A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente descripción proporciona métodos para tratar a un paciente con un fármaco sustrato para CYP3A4, en donde se trata al paciente con posaconazol. En algunas modalidades, el paciente suspende el tratamiento con posaconazol, espera durante al menos 2 días y después se trata con el fármaco sustrato para CYP3A4 tan pronto como sea seguro hacerlo. En algunas modalidades, el tratamiento con el fármaco sustrato para CYP3A4 se retrasa durante aproximadamente 2-42 días después de suspender el posaconazol. En algunas modalidades, se trata al paciente con una dosis reducida del fármaco sustrato para CYP3A4 durante aproximadamente 2-42 días.
MX2021000609A 2017-05-16 2018-11-14 Métodos de tratamiento con fármacos sustrato para cyp3a4. MX2021000609A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/596,585 US10376507B2 (en) 2017-05-16 2017-05-16 Method of treating a patient with a CYP3A4 substrate drug
US16/036,678 US20180333411A1 (en) 2017-05-16 2018-07-16 Methods of treatment
PCT/US2018/061141 WO2020018136A1 (en) 2017-05-16 2018-11-14 Methods of treatment with cyp3a4 substrate drugs

Publications (1)

Publication Number Publication Date
MX2021000609A true MX2021000609A (es) 2021-06-23

Family

ID=64269934

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2019013714A MX2019013714A (es) 2017-05-16 2017-05-16 Metodos de tratamiento.
MX2021000609A MX2021000609A (es) 2017-05-16 2018-11-14 Métodos de tratamiento con fármacos sustrato para cyp3a4.
MX2022013410A MX2022013410A (es) 2017-05-16 2019-11-15 Metodos de tratamiento.
MX2025000380A MX2025000380A (es) 2017-05-16 2021-01-15 Metodos de tratamiento con farmacos del sustrato cyp3a4

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019013714A MX2019013714A (es) 2017-05-16 2017-05-16 Metodos de tratamiento.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2022013410A MX2022013410A (es) 2017-05-16 2019-11-15 Metodos de tratamiento.
MX2025000380A MX2025000380A (es) 2017-05-16 2021-01-15 Metodos de tratamiento con farmacos del sustrato cyp3a4

Country Status (15)

Country Link
US (4) US10376507B2 (es)
EP (4) EP4082546A1 (es)
JP (6) JP2020520380A (es)
KR (3) KR20200010320A (es)
AU (10) AU2017414697B2 (es)
CA (2) CA3062770A1 (es)
DK (2) DK3426250T3 (es)
ES (2) ES2912373T3 (es)
FI (1) FI3716976T3 (es)
HR (1) HRP20220536T1 (es)
MX (4) MX2019013714A (es)
PL (1) PL3426250T3 (es)
SI (1) SI3426250T1 (es)
WO (2) WO2018212764A1 (es)
ZA (1) ZA202006746B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3394057T3 (pl) 2015-12-23 2022-08-22 Neurocrine Biosciences, Inc. Sposób syntetyczny wytwarzania di(4-metylobenzenosulfonianu) (S)-2-amino-3-metylobutanianu (2R,3R,11bR)-3-izobutylo-9,10-dimetoksy-2,3,4,6,7,11b-heksahydro-1H-pirydo[2,1-a]izochinolin-2-ylu
JP7107950B2 (ja) * 2017-01-27 2022-07-27 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２インヒビターを投与するための方法
JP2020520380A (ja) 2017-05-16 2020-07-09 ボウ リバー エルエルシー 処置法
US10857144B2 (en) 2017-05-16 2020-12-08 Bow River LLC Methods of treatment
US10835529B2 (en) 2017-05-16 2020-11-17 Bow River LLC Methods of treatment with CYP3A4 substrate drugs
US20220143011A1 (en) 2017-05-16 2022-05-12 Bow River LLC Methods of treatment with cyp3a4 substrate drugs
US11110098B2 (en) * 2017-06-07 2021-09-07 University Of Kansas Methods and medicaments for the treatment of renal cell carcinoma
MX2020002841A (es) 2017-09-21 2020-07-22 Neurocrine Biosciences Inc Formulacion de valbenazina de alta dosis y composiciones, metodos y kits relacionados con la misma.
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
EP3980072A4 (en) * 2019-06-05 2023-06-14 University of Georgia Research Foundation COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING HUMAN IMMUNODEFICIENCY VIRUS-ASSOCIATED PULMONARY HYPERTENSION
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
WO2021118924A2 (en) 2019-12-12 2021-06-17 Ting Therapeutics Llc Compositions and methods for the prevention and treatment of hearing loss
US11229644B1 (en) 2020-12-31 2022-01-25 Lake O'hara Llc Methods of treating psychiatric disorders in obese patients with brexpiprazole
WO2022146462A1 (en) * 2020-12-31 2022-07-07 Lake O'hara Llc Methods of treating psychiatric disorders in obese patients with brexpiprazole
CN112675175B (zh) * 2021-02-01 2022-11-01 天津济坤医药科技有限公司 布里格替尼在制备治疗特发性肺纤维化的药物中的应用
KR20230081687A (ko) * 2021-11-30 2023-06-07 에스케이케미칼 주식회사 마이크로조말 트리글리세라이드 전달 단백질 억제제의 섬유화 질환 치료 용도
WO2023141634A2 (en) * 2022-01-24 2023-07-27 Lake O'hara Llc Methods of treating psychiatric disorders in obese patients with brexpiprazole
CN117982655B (zh) * 2023-11-21 2024-10-15 北京大学人民医院 芳香化酶抑制剂治疗相关的疼痛动物模型构建方法及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7973970B2 (en) * 2000-08-09 2011-07-05 Ether Visuals Llc Preventing artifacts that may be produced when bottling PDL files converted from raster images
EP2023923A2 (en) * 2006-05-25 2009-02-18 Bristol-Myers Squibb Company Use of ixabepilone in combination with cyp3a4 inhibitors for pharmaceuticals
US7820681B1 (en) * 2009-01-14 2010-10-26 Mutual Pharmaceutical Company, Inc. Methods for concomitant administration of colchicine and a second active agent
US7816383B1 (en) * 2009-12-04 2010-10-19 Intermune, Inc. Methods of administering pirfenidone therapy
US20140221424A1 (en) 2013-01-30 2014-08-07 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for use in the treatment of cystic fibrosis
DK3223796T3 (da) 2014-11-25 2021-09-27 Curadigm Sas Farmaceutiske sammensætninger, fremstilling og anvendelser deraf
US10493024B2 (en) 2015-10-12 2019-12-03 Hk Tumescent Pharma Corporation Tumescent infiltration drug delivery of high subcutaneous drug concentrations with prolonged local and systemic effects and minimal local or systemic toxicity
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
KR20190067918A (ko) 2016-11-09 2019-06-17 사인패스 파마 인코포레이티드 채널병증을 야기하는 약물로부터 dmpc, dmpg, dmpc/dmpg, lysopg 및 lysopc의 보호 효과
US10835529B2 (en) 2017-05-16 2020-11-17 Bow River LLC Methods of treatment with CYP3A4 substrate drugs
JP2020520380A (ja) * 2017-05-16 2020-07-09 ボウ リバー エルエルシー 処置法

Also Published As

Publication number Publication date
MX2019013714A (es) 2020-07-14
AU2017414697B2 (en) 2020-03-05
AU2020203607A1 (en) 2020-06-25
AU2022228153A1 (en) 2022-09-29
AU2022204806B2 (en) 2025-04-24
AU2020203606B2 (en) 2020-07-09
AU2020202266B2 (en) 2020-05-14
ES2912373T3 (es) 2022-05-25
US20180333410A1 (en) 2018-11-22
AU2022228153B2 (en) 2025-04-24
JP2021510681A (ja) 2021-04-30
US20180333411A1 (en) 2018-11-22
EP3716976A1 (en) 2020-10-07
EP4461298A2 (en) 2024-11-13
JP2021059610A (ja) 2021-04-15
EP3426250A1 (en) 2019-01-16
AU2020203606A1 (en) 2020-06-25
AU2020203607B2 (en) 2020-07-09
EP3716976B1 (en) 2024-08-07
FI3716976T3 (fi) 2024-10-25
EP3716976A4 (en) 2021-02-17
US20190255043A1 (en) 2019-08-22
AU2020250281A1 (en) 2020-11-05
AU2020203608B2 (en) 2020-07-09
EP3426250B1 (en) 2022-03-23
CA3103793A1 (en) 2020-01-23
JP7353343B2 (ja) 2023-09-29
AU2020202100A1 (en) 2020-04-09
JP2020520380A (ja) 2020-07-09
WO2018212764A1 (en) 2018-11-22
EP4461298A3 (en) 2025-01-22
AU2020250281B2 (en) 2022-07-28
AU2020202100B2 (en) 2020-07-02
WO2020018136A1 (en) 2020-01-23
US20180333409A1 (en) 2018-11-22
AU2017414697A1 (en) 2019-11-07
KR102805232B1 (ko) 2025-05-13
AU2020203608A1 (en) 2020-06-25
JP2022022264A (ja) 2022-02-03
HRP20220536T1 (hr) 2022-06-10
MX2022013410A (es) 2022-11-14
AU2020202266A1 (en) 2020-04-23
EP4082546A1 (en) 2022-11-02
MX2025000380A (es) 2025-02-10
KR20200010320A (ko) 2020-01-30
US10376507B2 (en) 2019-08-13
AU2022204806A1 (en) 2022-11-10
CA3062770A1 (en) 2018-11-22
AU2018432858A1 (en) 2021-01-07
JP2023021260A (ja) 2023-02-10
JP2023174661A (ja) 2023-12-08
PL3426250T3 (pl) 2022-08-08
KR20210045400A (ko) 2021-04-26
DK3426250T3 (da) 2022-05-16
DK3716976T3 (da) 2024-10-28
JP7698009B2 (ja) 2025-06-24
SI3426250T1 (sl) 2022-09-30
JP6984024B2 (ja) 2021-12-17
KR20210010663A (ko) 2021-01-27
ES2993832T3 (en) 2025-01-10
ZA202006746B (en) 2023-03-29
EP3426250A4 (en) 2020-05-06

Similar Documents

Publication Publication Date Title
MX2021000609A (es) Métodos de tratamiento con fármacos sustrato para cyp3a4.
MX2021004821A (es) Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.
CL2018000706A1 (es) Derivados de pirazolopirimidina como inhibidores btk para el tratamiento del cancer.
MX387283B (es) Tratamiento del cancer con tg02.
MX378872B (es) Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia.
WO2019040106A3 (en) COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES
BR112017023170A2 (pt) dispositivo de banho medicinal e seu uso
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
MX379359B (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
MX2018008640A (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano.
SV2017005444A (es) Método para tratar prevenir o reducir el riesgo de infección cutánea
CO2019003865A2 (es) Proteína terapéutica
AR095594A1 (es) Métodos para tratar infecciones en pacientes con sobrepeso y obesos usando antibióticos
PH12018501769A1 (en) Medicament for treatment of diabetic foot infections
EA201891008A3 (ru) Лечение симптомов, связанных с андроген-депривационной терапией
EA201650085A1 (ru) Способ лечения опухолевого заболевания и способ селективного ингибирования роста опухолевых клеток с помощью производного хиноксалин-1,4-диоксида
MX2020008193A (es) Nemolizumab en el tratamiento de dermatitis atópica con excoriación moderada a severa.
UA125566U (uk) Спосіб лікування хворих на феліноз
EA201692163A1 (ru) Лекарственное средство для лечения пациентов с тиннитусом
RU2014116784A (ru) Способ лечения заболеваний пародонта
UA115417U (xx) Спосіб профілактики та лікування гіпоксичних змін при карбоперитонеумі
UA109281U (uk) Спосіб комплексного лікування аспірин-індукованої гастропатії з застосуванням гастроцитопротективної терапії у хворих на ішемічну хворобу серця
EA201692164A1 (ru) Лекарственное средство для лечения пациентов с тиннитусом
UA96488U (uk) Спосіб лікування порушень гемоваскулярного гемостазу у хворих на ішемічну хворобу серця
PL414619A1 (pl) Zastosowanie medyczne ekstraktu z ziela Centaurea borysthenica Gruner w leczeniu kardioprotekcyjnym